One hundred years of migraine research: Major clinical and scientific observations from 1910 to 2010

Headache

Volumn 51, Issue 5, 2011, Pages 752-778

  Tfelt Hansen, Peer C ^a   Koehler, Peter J ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Sittard Geleen Heerlen   (Netherlands)

Author keywords

1910 2010; classification; history; migraine gene; migraine research; regional cerebral blood flow

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; ERGOTAMINE; METHYSERGIDE; NEUROTRANSMITTER; SEROTONIN; SUMATRIPTAN;

ALLODYNIA; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN STEM; CHANNELOPATHY; CLINICAL OBSERVATION; DEPRESSION; DISEASE CLASSIFICATION; DRUG ISOLATION; DRUG MECHANISM; ELECTROENCEPHALOGRAM; GENETIC ANALYSIS; HEAD; HEADACHE; HEMIPLEGIC MIGRAINE; HUMAN; MENINX; MIGRAINE; MIGRAINE WITH AURA; NEUROGENIC INFLAMMATION; NEUROLOGIC DISEASE; NEUROSURGERY; PAIN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCIENTIFIC LITERATURE; SCOTOMA; TECHNOLOGY; VASCULAR DISEASE; VASODILATATION;

EID: 79955375829     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.01892.x     Document Type: Review

References (205)

1. Wolff HG,. Headache and Other Head Pain. New York: Oxford University Press; 1948.
2. Wolff HG,. Headache and Other Head Pain, 2nd edn. New York: Oxford University Press; 1963.
3. Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 1st edn. New York: Ravens Press; 1993.
4. Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 2nd edn. Philadelphia, PA: Lippincott Williams and Wilkins; 2000.
5. Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 3rd edn. Philadelphia, PA: Lippincott Williams and Wilkins; 2006.
6. Stoll A,. Zur Kenntnis der Mutterkornalkaloide. Verh Schweiz Naturf Ges. 1918; 101: 190-191.
7. Graham JR, Wolff HG,. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry. 1938; 39: 737-763.
8. Ray BS, Wolff HG,. Experimental studies on headache. Pain-sensitive structures of the head and their significance in headache. Arch Surg. 1940; 41: 813-856.
9. Lashley KS,. Patterns of cerebral integration indicated by the scotomas of migraine. Arch Neurol Psych. 1941; 46: 331-339.
10. LeÀo AAP,. Spreading depression of activity in cerebral cortex. J Neurophysiol. 1944; 7: 159-390.
11. Sicuteri F,. Prophylactic and therapeutic properties of 1-methyllysergic acid butanolamide in migraine. Int Arch Allerg. 1959; 15: 300-307.
12. Olesen J, Larsen B, Lauritzen M,. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol. 1981; 9: 344-352. (Pubitemid 11106551)
13. Lauritzen M, JÀrgensen MB, Diemer NH, Gjedde A, Hansen J,. Persistent oligemia of rat cerebral cortex in the wake of spreading depression. Ann Neurol. 1982; 12: 469-474. (Pubitemid 12006883)
14. Moskowitz MA,. The neurobiology of vascular head pain. Ann Neurol. 1984; 16: 157-168. (Pubitemid 14062662)
15. Headache Classication Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988; 8 (Suppl 7): 1-96.
16. Humphrey PPA, Feniuk W, Perren MJ, Connor HE,. GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol. 1988; 94: 1123-1132.
17. Goadsby PJ, Edvinsson L, Ekman R,. Vasoactive peptide release in the extracerebral circulation of humans during migraine attacks. Ann Neurol. 1990; 28: 183-187. (Pubitemid 20244522)
18. Weiller C, May A, Limroth V, et al,. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995; 1: 658-660.
19. Ophoff RA, Terwindt GM, Vergouwe MN, et al,. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca21 channel gene CACNL1A4. Cell. 1996; 87: 543-552. (Pubitemid 26374327)
20. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH,. An association between migraine and cutaneous allodynia. Ann Neurol. 2000; 47: 614-624. (Pubitemid 30261897)
21. Koehler PJ, Isler H,. The early use of ergotamine in migraine. Edward Woakes' report of 1868, its theoretical and practical background and its international reception. Cephalalgia. 2002; 22: 686-691. (Pubitemid 36609339)
22. Dale HH,. On some physiological actions of ergot. J Physiol (Lond). 1906; 34: 163-206.
23. Tfelt-Hansen PC, Koehler PJ,. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia. 2008; 28: 877-886.
24. Rothlin E,. Contribution À la méthode chimique d'exploration du systÀme sympathique. Rev Neurol. 1926; 33: 1108-1113.
25. Maier HW,. L'ergotamine, inhibiteur du sympathique étudié en clinique, comme moyen d'exploration et comme agent thérapeutique. Rev Neurol. 1926; 33: 1104-1108.
26. Trautmann E,. Die Beeinflussung migräneartiger Zustände durch ein sympathikushemmendes Mittel (Gynergen). Münch Med Wochenschr. 1928; 75: 513.
27. Tzanck MA,. Le traitement des migraines par le tartrate d'ergotamine. Bull Soc Méd Paris. 1928; 44: 1057-1061.
28. Du Bois-Reymond E,. Zur Kenntniss der Hemikrania. Arch Anat Physiol Wissensch Med. 1860; 461-468.
29. Schiller F,. The migraine tradition. Bull Hist Med. 1975; 49: 1-19.
30. Tzanck MA,. Le traitement des migraines par le tartrate d'ergotamine. Bull Mém Soc Méd Des HÀp Paris. 1931; 55: 1663.
31. Brock S, O'Sullivan M, Young D,. The effect of non-sedative drugs and other measures in migraine, with special reference to ergotamine tartrate. Am J Med Sci. 1934; 188: 253-260.
32. Lennox WG,. The use of ergotamine tartrate in migraine. N Engl J Med. 1934; 210: 1061-1065.
33. Logan AH, Allen EV,. The treatment of migraine with ergotamine tartrate. Proc Mayo Clin. 1934; 9: 585-588.
34. Lennox WG, von Storch TJC,. Experience with ergotamine tartrate in 120 patients with migraine. JAMA. 1935; 105: 169-171.
35. Tfelt-Hansen P,. The effect of ergotamine on the arterial system in man. Acta Pharmacol Toxicol. 1986; 59 (Suppl 3): 1-30.
36. O'Sullivan ME,. Termination of one thousand attacks of migraine with ergotamine tartrate. JAMA. 1936; 107: 1208-1212.
37. Lennox WG,. Ergonovine versus ergotamine as a terminator of migraine headaches. Am J Med Sci. 1938; 195: 458-468.
38. Tfelt-Hansen P, Saxena PR, Dahlöf C, et al,. Ergotamine in the acute treatment of migraine-European Consensus. Brain. 2000; 123: 9-18. (Pubitemid 30037964)
39. Koehler PJ,. Etiology and pathophysiology of headache in the early 17th century, as illustrated by the work of Johan van Beverwijck. Cephalalgia. 1997; 17: 817-821. (Pubitemid 128721586)
40. Nie H, Arendt-Nielsen L, Andersen H, Graven-Nielsen T,. Temporal summation of pain evoked by mechanical stimulation in deep and superficial tissue. J Pain. 2005; 6: 348-355. (Pubitemid 40804339)
41. Staud R, Koo E, Robinson ME, Price DD,. Spatial summation of mechanically evoked muscle pain and paiful aftersensations in normal subjects and fibromyalgia patients. Pain. 2007; 130: 177-187. (Pubitemid 46843465)
42. Staud R, Robinson ME, Price DD,. Temporal summation of second pain and its maintenance are useful for characterizing widespread central sensitization of fibromyalgia patients. J Pain. 2007; 8: 893-901. (Pubitemid 350008124)
43. Olesen J, Burstein R, Ashina M, Tfelt-Hansen P,. Origin of pain (nociception) in migraine. Lancet Neurol. 2009; 8: 679-690.
44. Airy H,. On a distinct form of transient hemiopsia. Philos Trans R Soc Lond B Biol Sci. 1870; 160: 247-250.
45. Liveing E,. On Megrim, Sick-Headache, and Some Allied Disorders: A Contribution to the Pathology of Nerve-Storms. London: Churchill; 1873.
46. Koehler PJ,. Brown-Séquard's comment on Du Bois-Reymond's "hemikrania sympathicotonica." Cephalalgia. 1995; 15: 370-372.
47. Plant GT,. The fortification spectra of migraine. BMJ. 1986; 293: 1613-1620.
48. Richter H,. Die migraine., Bumke O, Foerster O, eds. Handbuch Der Neurologie, 17th edn. Berlin: Springer; 1935: 166-345.
49. Jolly F,. Àber Flimmerskotom und Migräne. Berlin Klin Wschr. 1902; 42: 973-976.
50. Teive HAG, Kowacs PA, MaranhÀo F, Piovesan EJ, Werneck LC,. LeaÀμ's cortical spreading depression. From experimental "artifact" to physiological principle. Neurology. 2005; 65: 1455-1459. (Pubitemid 41552779)
51. LeÀo AAP,. Pial circulation and spreading depression of activity in cerebral cortex. J Neurophysiol. 1944; 7: 391-396.
52. LeÀo AAP, Morrison RS,. Propagation of spreading cortical depression. J Neurophysiol. 1945; 8: 833-845.
53. Bures J, Buresova O, Krivanek J,. The Mechanisms and Applications of Leˣo Spreading Depression of Electroencephalographic Activity. New York: Academic Press; 1974.
54. Milner PM,. Note on the the correspondence between the scotomas of migraine and spreading depression of LeÀo. Electroencephalogr Clin Neurophysiol. 1958; 10: 75.
55. Smith JM, Bradley DP, James MF, Huang CL-H,. Physiological studies of cortical spreading depression. Biol Rev. 2006; 81: 457-481. (Pubitemid 44711866)
56. Charles A, Brennan KC,. Cortical spreading depression-New insights and persistent questions. Cephalalgia. 2009; 29: 1115-1124.
57. Koehler P, Tfelt-Hansen P,. History of methysergide in migraine. Cephalalgia. 2008; 28: 1126-1135.
58. Wolff HG, Ostfeld AM, Chapman LF, Goodell H,. Studies in headache: A summary of evidence implicating a locally active chemical agents in migraine. Trans Amer Neurol Ass. 81st Meeting 1956;81st Meeting: 356.
59. Sicuteri F, Testi A, Anselmi B,. Biochemical investigations in headache: Increase in hydroxyindolacetic acid excretion during migraine attacks. Int Arch Allergy. 1961; 19: 55-58.
60. Southwell N, Williams JD, MacKenzie I,. Methysergide in the prophylaxis of migraine. Lancet. 1964; 1: 523-524.
61. Pedersen E, MÀller CE,. Methysergide in migraine prophylaxis. Clin Pharmacol Ther. 1966; 7: 520-526.
62. Graham JR, Suby H, LeCompte PR, Sadowsky NL,. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med. 1966; 274: 359-368.
63. Silberstein SD,. Methysergide. Cephalalgia. 1998; 18: 421-435. (Pubitemid 28459458)
64. Graham JR,. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci. 1967; 254: 1-12.
65. Saxena PR,. Selective vasoconstriction in carotid vascular bed by methysergide: Possible relevance to its antimigraine effect. Eur J Pharmacol. 1974; 27: 99-105.
66. Apperley E, Feniuk W, Humphrey PPA, Levy GP,. Evidence for two types of excitatory receptor for 5-hydroxytryptamine in dog isolated vasculature. Br J Pharmacol. 1980; 68: 215-224. (Pubitemid 10108713)
67. SkinhÀj E,. Hemodynamic studies within the brain during migraine. Arch Neurol. 1973; 29: 95-98.
68. Sveinsdottir E, Larsen B, Rommer P, Lassen NA,. A multidetector scintillation camera with 254 channels. J Nucl Med. 1977; 18: 168-174. (Pubitemid 8036427)
69. + during spreading depression. Acta Physiol Scand. 1980; 10: 1-6. (Pubitemid 10124332)
70. Lauritzen M, Olsen TS, Lassen NA, Paulson OB,. Changes in regional cerebral blood flow during the course of classic migraine attacks. Ann Neurol. 1983; 13: 633-641. (Pubitemid 13103461)
71. Lauritzen M, Olsen TS, Lassen NA, Paulson OB,. Regulation of regional cerebral blood flow during and between migraine attacks. Ann Neurol. 1983; 14: 569-572. (Pubitemid 14239726)
72. Lauritzen M, Olesen J,. Regional cerebral blood flow during migraine attacks by Xenon-133 inhalation and emission tomography. Brain. 1984; 107: 447-461. (Pubitemid 14108830)
73. Lauritzen M,. Cortical spreading depression as a putative mechanism. Trends Neurosci. 1987; 10: 8-13. (Pubitemid 17230794)
74. Andersen AR, Friberg L, Olsen TS, Olesen J,. Delayed hyperamia following hypoperfusion in classic migraine. Single photon emission tomographic demonstration. Arch Neurol. 1988; 45: 154-159. (Pubitemid 18054530)
75. Olesen J, Tfelt-Hansen P, Henriksen L, Larsen B,. Common migraine may not be initiated by cerebral ischemia. Lancet. 1981; II: 438-440. (Pubitemid 11048354)
76. Olesen J, Friberg L, Olsen TS, et al,. Timing and topography of cerebral blood flow, aura and headache during migraine attacks. Ann Neurol. 1990; 28: 791-798.
77. Hadjikhani N, Sanchez Del Rio M, Wu O, et al,. Mechanism of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA. 2001; 98: 4687-4692. (Pubitemid 32295037)
78. Woods RP, Iacoboni M, Mazziotta JC,. Brief report: Bilateral spreading hypoperfusion during spontaneous migraine headache. N Engl J Med. 1994; 331: 1689-1692. (Pubitemid 24373622)
79. Olesen J,. Understanding the biological basis of migraine. N Engl J Med. 1994; 331: 1713-1714.
80. Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G,. Hypothalamic activation in spontaneous migraine attacks. Headache. 2007; 47: 1418-1426. (Pubitemid 350209521)
81. Afridi SK, Mathau MS, Lee L, Kaube H, Friston KJM, Fackowiack RS,. A PET study exploring the laterality of brain stem activation in migraine using glyceryl trinitrate. Brain. 2005; 128: 932-939. (Pubitemid 40516929)
82. Cutrer FM, Sorensen AG, Weisskoff RM, et al,. Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol. 1998; 43: 25-31. (Pubitemid 28124645)
83. Cao Y, Welch KM, Aurora S, Vikingstad EM,. Functional MRI-BOLD of visually triggered headache in patients with migraine. Arch Neurol. 1999; 56: 548-554. (Pubitemid 29218149)
84. Tfelt-Hansen P,. History of migraine with aura and cortical spreading depression from 1941 and onward. Cephalalgia. 2010; 30: 780-792.
85. Piper RD, Lambert GA, Duckworth JW,. Cortical blood flow changes during spreading depression in cats. Am J Physiol. 1991; 261: H06-102.
86. Shimazawa M, Hara H,. An experimental model of migraine with aura: Cortical hypoperfusion following spreading depression in the awake and freely moving rat. Clin Exp Pharmacol Physiol. 1996; 23: 890-892. (Pubitemid 26361711)
87. Lauritzen M,. Long-lasting reduction of cortical blood flow of the brain after spreading depression with preserved autoregulation and impaired CO2 response. J Cereb Blood Flow Metab. 1984; 4: 546-554. (Pubitemid 15222299)
88. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA,. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002; 8: 135-142.
89. Gursoy-Ozdemir Y, Qui J, Matsuoka N, et al,. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest. 2004; 113: 1447-1455. (Pubitemid 39071700)
90. Edvinsson L, Tfelt-Hansen P,. The blood-brain barrier in migraine treatment. Cephalalgia. 2008; 28: 1245-1258.
91. van den Maagdenberg AM, Pietrobono D, Pizzoruso T, et al,. A CACNA1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron. 2004; 41: 701-710. (Pubitemid 38326833)
92. Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA,. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006; 59: 652-661.
93. Strong AJ, Fabricius M, Boutelle MG, et al,. Spreading and synchronous depressions of cortical activity in acutely injured human brain. Stroke. 2002; 33: 2738-2743. (Pubitemid 35462836)
94. Fabricius M, Fuhr S, Bhatia R, et al,. Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex. Brain. 2006; 129: 778-790. (Pubitemid 43278239)
95. Fabricius M, Fuhr S, Willumsen L, et al,. Association of seixures with cortical spreading depression and peri-infarct depolarisation in the acutely injured human brain. Clin Neurophysiol. 2008; 119: 1973-1984.
96. Moskowitz MA, Reinhard JF Jr, Romero J, Melamed E, Pettibone DJ,. Neurotransmittors and the fifth cranial nerve: Is there a relation to the headache phase of migraine? Lancet. 1979; 2: 883-885.
97. Dohmen C, Sakowitz OW, Fabricius M, et al,. Spreading depolarizations occur in human ischemic stroke with high incidence. Ann Neurol. 2008; 63: 720-728. (Pubitemid 351945531)
98. Mayberg M, Langer RS, Zervas NT, Moskowitz MA,. Perivascular meningeal projections from cat trigeminal ganglia: Possible pathways for vascular headache. Science. 1981; 213: 228-230. (Pubitemid 11060572)
99. Mayberg MC, Zervas NT, Moskowitz MA,. Trigeminal projections to supratentorial pial and dural blood vessels in cats demonstrated by horseradish peroxidase histochemistry. J Comp Neurol. 1984; 223: 46-56. (Pubitemid 14186772)
100. Moskowitz MA, Brody M, Liu-Chen LY,. In vitro release immunoreactive substance P from putative afferent nerve endings in bovine pia arachnoid. Neuroscience. 1983; 9: 809-814. (Pubitemid 13039164)
101. Norregaard TV, Moskowitz MA,. Substance P and the sensory innervation of intracranial and extracranial feline cephalic arteries. Implications for vascular pain mechanism in man. Brain. 1985; 108: 517-533. (Pubitemid 15064807)
102. Markowitz S, Saito K, Moskowitz MA,. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci. 1987; 7: 4129-4136. (Pubitemid 18012423)
103. Saito K, Markowitz S, Moskowitz MA,. Ergot alkaloids block neurogenic extravasation in dura mater: Proposed action in vascular headaches. Ann Neurol. 1988; 24: 732-737. (Pubitemid 19019027)
104. Buzzi MG, Sakas DE, Moskowitz MA,. Indomethacin and acetylsalicyclic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol. 1989; 165: 251-258. (Pubitemid 19181793)
105. Buzzi MG, Moskowitz MA,. Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia. 1991; 11: 165-168.
106. Buzzi MG, Moskowitz MA, Perouka SJ, Byun B,. Further charaterization of the putative 5-HT receptors which mediates blockade of neurogenic plasma extravasation in rat dura mater. Br J Pharmacol. 1991; 103: 1421-1428.
107. Buzzi MG, Dimitriadou V, Theoharides TC, Moskowitz MA,. 5-hydroxytryptamine receptor agonists for the abortive treatment of vascular mast cell, endothelial and platelet activation within the dura mater after trigeminal stimulation. Brain Res. 1992; 583: 137-149.
108. Johnson KW, Bolay H,. Neurogenic inflammatory mechanisms. In:, Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2006: 309-319.
109. 1 receptor antagonist in the acute treatment of migraine. Cephalalgia. 1998; 18: 392.
110. May A, Gijsman HJ, Wallnöfer A, Jones R, Diener HC, Ferrari MD,. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in abortive migraine attacks. Pain. 1996; 67: 375-378. (Pubitemid 26375354)
111. Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT,. Ineffectiveness of neurkinin-1 antagonist in acute migraine: A crossover study. Cephalalgia. 1997; 17: 785-790. (Pubitemid 27505105)
112. Roon K, Diener HC, Ellis P, et al,. CP-122,288 blocks neurogenic inflammation, but is not effective in aborting migraine migraine attacks: Results of two controlled clinical studies. Cephalalgia. 1997; 17: 245.
113. Data J, Britch K, Westergaard N, et al,. A double-blind study of ganaxolone in the treatment of migraine headaches with and without aura in premenopausal females. Headache. 1998; 38: 380.
114. Lee WS, Limmroth V, Ayata C, et al,. Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation. Br J Pharmacol. 1995; 116: 1661-1667.
115. Iversen HK, Olesen J, Tfelt-Hansen P,. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain. 1989; 38: 17-24. (Pubitemid 19184833)
116. Thomsen LL, Kruuse C, Iversen HK, Olesen J,. A nitric oxide donor (nitroglycerin) induces genuine migraine attacks. Eur J Neurol. 1994; 1: 73-80. (Pubitemid 2141297)
117. Reuter U, Bolay H, Jansen-Olesen I, et al,. Delayed inflammation in rat meninges: Implication for migraine pathophysiology. Brain. 2001; 124: 2490-2502. (Pubitemid 33134937)
118. Olesen J,. Classification. In:, Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 1st edn. New York: Ravens Press; 1993: 9-14.
119. Ad Hoc Committee on Classification of Headache. Classification of headache. JAMA. 1962; 179: 717-718.
120. Humphrey PP,. The discovery and development of the triptans, a major therapeutic breakthrough. Headache. 2008; 48: 685-687. (Pubitemid 351678009)
121. Tfelt-Hansen P, De Vries P, Saxena PR,. Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000; 60: 1259-1287. (Pubitemid 32039386)
122. Saxena PR, Tfelt-Hansen P,. Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In:, Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2006: 469-503.
123. Headache Classication Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl 4): 9-160.
124. Headache Classification Committee, Olesen J, Bousser MG, Diener HC, et al,. New appendix criteria for a broader concept of chronic migraine. Cephalalgia. 2006; 26: 742-746.
125. Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET,. Serotonin and migraine. Ann N Y Acad Sci. 1990; 600: 587-598.
126. Peroutka SJ,. Sumatriptan in acute migraine: Pharmacology and review of world experience. Headache. 1990; 30 (Suppl 2): 554-560.
127. Kimball RW, Friedman AP, Valeejo E,. Effect of serotonin in migraine patients. Neurology. 1960; 10: 107-111.
128. Anthony M, Hinterberger H, Lance JW,. Plasma serotonin in migraine and stress. Arch Neurol. 1967; 16: 544-552.
129. Saxena PR, Verdouw PD,. Effects of methysergide and 5-hydroxytryptamine on carotid blood flow distribution in pigs: Further evidence for the presence of atypical 5-HT receptors. Br J Pharmacol. 1984; 82: 817-825.
130. Feniuk W, Humphrey PP, Perren MJ, Watts AD,. A comparison of 5-hydroxytryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein: Evidence for different receptor types obtained by use of selective agonists and antagonists. Br J Pharmacol. 1985; 86: 697-704. (Pubitemid 16235385)
131. Humphrey PP, Feniuk W, Perren MJ, et al,. GR43175, a selective agonist for the 5-HT-1-like receptor in the dog isolated saphenous vein. Br J Pharmacol. 1988; 94: 1123-1132.
132. Connor HE, Feniuk W, Humphrey PP,. Characterization of 5-HT receptors mediating contraction of canine and primate basilar artery by use of GR43175, a selective 5-HT1-like receptor agonist. Br J Pharmacol. 1989; 96: 379-387. (Pubitemid 19045113)
133. Parsons AA, Whalley ET, Feniuk W, Connor HE, Humphtey PP,. 5-HT1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Br J Pharmacol. 1989; 96: 434-440. (Pubitemid 19045120)
134. Humphrey PPA, Feniuk W, Motevalian M, et al,. The vasoconstrictoraction of sumatriptan on human isolated dura mater. In:, Fozard JR, Saxena PR, eds. Serotonin: Molecular Biology, Receptors and Functional Effects. Basel: BirkauserVerlag; 1991: 421-429.
135. Feniuk W, Humphrey PPA,. The development of a highly selective 5-HT, receptor agonist, sumatriptan, for the treatment of migraine. Drug Dev Res. 1992; 26: 235-240.
136. Saxena PR, Tfelt-Hansen P,. Triptans, 5-HT1B/1D receptoragonists, in the acute treatment of migraine. In:, Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 2nd edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2000: 411-438.
137. Maassen Van Den, Brink A, Saxena PR,. Coronary vasoconstrictor potential of triptans: A review of in vitro pharmacologic data. Headache. 2004; 44: S13-S19. (Pubitemid 38685541)
138. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skagges H Jr,. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991; 265: 2831-2835.
139. Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med. 1991; 325: 316-321.
140. Mathew NT, Dexter J, Couch J, et al,. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992; 49: 1271-1276.
141. Tfelt-Hansen P,. Efficacy and adverse events of subcutaneous, oral and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat. Cephalalgia. 1998; 18: 532-538. (Pubitemid 28526841)
142. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ,. Oral triptans (serotonin 5-HT1B/1D) agonists) in acute migraine: A meta-analysis of 53 trials. Lancet. 2001; 358: 1668-1675. (Pubitemid 33124324)
143. Brandes JL, Kudrow D, Stark SR, et al,. Sumatriptan-naproxen for acute migraine. A randomized trial. JAMA. 2007; 297: 1443-1454. (Pubitemid 46556470)
144. Rosenfeld MG, Mermod JJ, Amara SG, et al,. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature. 1983; 304: 129-135. (Pubitemid 13079138)
145. Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J,. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: Trigeminal origin and co-existence with substance P. Neurosci Lett. 1985; 62: 131-136. (Pubitemid 16205735)
146. McCulloch J, Udmann R, Kingman TA, Edvinsson L,. Calcitonin gene-related peptide: Functional role in cerebrovascular regulation. Proc Natl Acad Sci USA. 1986; 83: 5731-5735. (Pubitemid 16001291)
147. Edvinsson L, Fredholm BB, Hamel E, Jansen I, Verrecchia C,. Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or rease of an endothelium-derived relaxing factor in the cat. Neurosci Lett. 1985; 58: 213-217. (Pubitemid 15017193)
148. Goadsby PJ, Edvinsson L, Ekman R,. Release of vasoactive peptides in the extracerebral circulation of humans and cat during activation of the trigeminovascular system. Ann Neurol. 1988; 23: 193-196. (Pubitemid 18081459)
149. Goadsby PJ, Edvinsson L,. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993; 33: 48-56. (Pubitemid 23009909)
150. Doods H, Hallermayer G, Wu D, et al,. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000; 129: 420-423. (Pubitemid 30083862)
151. Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J,. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol. 2005; 58: 561-568. (Pubitemid 41377219)
152. Daugaard D, Lassen LH, Iversen HK, Olsen J,. No elevation of plasma levels of CGRP in external jugular venous blood in spontaneous migraine or nitroglycerin-induced attacks. Poster presented at the International Headache Research Seminar in Copenhagen, March 2009.
153. Tfelt-Hansen P,. Calcitonin gene-related peptide in external jugular vein during migraine and cluster headache. Is it increased? In:, Olesen J, ed. Role of Calcitonin Gene-Related Peptide (CGRP) and Adrenomedullin (AM) in Migraine. Frontiers in Headache Research. Oxford: University Press; (in press).
154. Cady RK, Vause CV, Ho TW, Bigal E, Durham PL,. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009; 49: 1258-1266.
155. Bellamy JL, Cady RK, Durham PL,. Salivary levels of CGRP and VIP in rhinosinuitis and migraine patients. Headache. 2006; 46: 24-33.
156. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J,. CGRP may play a causative role in migraine. Cephalalgia. 2002; 22: 54-61. (Pubitemid 34626025)
157. Olesen J, Diener HC, Husstedt IW, et al,. Calcitonin gene-trlated peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350: 1104-1110. (Pubitemid 38298990)
158. Ho TW, Mannix LK, Fan X, et al,. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008; 70: 1304-1212.
159. Ho TW, Ferrari MD, Dodick DW, et al,. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compated with zolmitriptan for acute migraine: A randomized, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372: 2115-2123.
160. Connor KM, Shapiro RE, Diener H-C, et al,. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009; 73: 970-977.
161. Petersen KA, Birk S, Lassen LH, et al,. The CGRP-antagonist, BIBN4096BS, does not affect central or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005; 25: 139-147. (Pubitemid 40193957)
162. Villalon CM, Olesen J,. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009; 124: 309-323.
163. Diener HC, May A,. New aspects of migraine pathophysiology: Lessons learned from positron emission tomography. Curr Opin Neurol. 1996; 9: 199-201. (Pubitemid 26242669)
164. Russell MB, Olesen J,. Increased familial risk and evidence of genetic factor in migraine. BMJ. 1995; 311: 541-544.
165. Nyholt DR, Gillespie NG, Heath AC, Merikangas KR, Duffy DL, Martin NG,. Latent class and genetic analysis does not support migraine with aura and migraine without aura as separate entities. Genet Epidemiol. 2004; 26: 231-244. (Pubitemid 38420336)
166. Lighart L, Boomsma DI, Martin NG, Stubbe JH, Nyholt DR,. Migraine with aura and migraine without aura are not distinct entities: Further evidence from a large Dutch population study. Twin Res Hum Gen. 2006; 9: 54-63. (Pubitemid 43384793)
167. Joutel A, Bousser M-G, Biousse V, et al,. A gene for familial hemiplegic migraine maps to chromosome 19. Nature Genet. 1993; 5: 40-45. (Pubitemid 23261516)
168. Joutel A, Ducros A, Vahedi K, Labauge P, Delrieu O, Pisard N,. Genetic hererogeneity of familial hemiplegic migraine. Am J Hum Genet. 1994; 55: 1166-1172. (Pubitemid 24355571)
169. Ophoff RA, van Eijk R, Sandkuijl LA, et al,. Genetic heterogeneity of familial hemiplegic migraine. Genomics. 1994; 22: 21-26. (Pubitemid 24234083)
170. Hovatta I, Kallela M, Färkila M, Peltonen L,. Familial migraine: Exclusion of the susceptibility gene from the reported locus of familial hemiplegic migraine on 19p. Genomics. 1994; 23: 707-709. (Pubitemid 24338662)
171. May A, Ophoff RA, Terwindt GM, et al,. Familial hemiplegic locus on 19p13 is involved in the common of migraine and without aura. Human Genet. 1995; 96: 604-608.
172. Ophoff RA, Terwindt GM, Vergouwe MN, et al,. A 3-Mb region for familial hemiplegic migraine locus on 19p13.2: Exclusion of PRKCSH as a candidate gene. Dutch Migraine Genetic Research Group. Eur J Hum Genet. 1996; 4: 321-328. (Pubitemid 27075617)
173. Marconi R, De Fusco M, Aridon P, et al,. Familial hemiplegic migraine type 2 is linked to 0.9 Mb region on chromosome 1q23. Ann Neurol. 2003; 53: 376-381. (Pubitemid 36258641)
174. De Fusco M, Marconi K, Silvestri L, et al,. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pimp alpha2 subunit associated with familial hemiplegic migraine. Nat Gen. 2003; 33: 192-196. (Pubitemid 36177073)
175. Dichgans M, Freilinger T, Eckstein G, et al,. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet. 2005; 336: 371-377. (Pubitemid 41073954)
176. Ferrari MD, Haan J, Palotie A,. Genetics of migraine. In:, Olesen J,
177. Peroutka SJ, Wilhoit T, Jones K,. Clinical susceptibility to migraine with migraine is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology. 1997; 49: 201-206. (Pubitemid 27328703)
178. Peroutka SJ, Price SC, Wilhoit TL, Jones KW,. Comorbid migraine with aura, anxiety and depression is associated with dopamine D2 receptor (DRD2) NcoI alleles. Mol Med. 1998; 4: 14-21. (Pubitemid 28134328)
179. Paterna S, Di Pasquale P, D'Angelo A, et al,. Angiotensin-converting enzyme gene deletion determines an increase in the frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol. 2000; 43: 133-136. (Pubitemid 30189532)
180. Nyholt DR, Dawkins JL, Brimage PJ, Goadsby PJ, Nicholson GA, Griffiths LR,. Evidence for an X-linked genetic component in famial typical migraine. Hum Mol Genet. 1998; 7: 459-463. (Pubitemid 28120636)
181. Kowa H, Yasul K, Takeshima T, Urakami K, Sakai F, Nakashima K,. The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am J Med Genet. 2000; 96: 762-764.
182. Martelletti P, Lulli P, Morellini M, et al,. Chromosone 6p-encoded HLA-DR2 determinant discriminates migraine without aura from migraine with aura. Hum Immunol. 1999; 60: 69-74. (Pubitemid 29057858)
183. Martelletti P, Brioli G, Lulli P, Morelli M, Giacovazzo M, Trabace S,. Tumor necrosis factor B gene polymorphism contributes to susceptibility to migraine without aura. J Headache Pain. 2000; 1: 119-132.
184. Dichgans M, Forderreuther S, Deitrich M, Pfaffenrath V, Gasser J,. The D2 receptor Nco1 allele: Absence of allelic association with migraine with aura. Neurology. 1998; 51: 928. (Pubitemid 28449313)
185. McCarthy LC, Hosford DA, Riley JH, et al,. Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics. 2001; 78: 135-149. (Pubitemid 34001417)
186. Netzer C, Freudenberg J, Heinze A, et al,. Replication study of the insulin receptor gene in migraine with aura. Genomics. 2008; 91: 503-507.
187. Nyholt DR, LaForge KS, Kallela M, et al,. A high-density association screen of 155 ion transport genes for involvement with common migraine. Hum Mol Genet. 2008; 17: 3318-3331.
188. de Vries B, Frants RR, Ferrari MD, van den Maagdenberg AM,. Molecular genetics of migraine. Human Genet. 2009; 126: 115-132.
189. Hansen JM, Thomsen LL, Olesen J, Ashina M,. Familial hemiplegic migraine type 1 shows no hypersensivity to nitric oxide. Cephalalgia. 2008; 28: 496-505. (Pubitemid 351502557)
190. Hansen P, Thomsen LL, Marconi R, Casari G, Olesen J, Ashina M,. Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine. Cephalalgia. 2008; 28: 367-375. (Pubitemid 351341452)
191. Christiansen I, Thomsen LL, Daugaard D, Ulrich V, Olesen J,. Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia. 1999; 19: 660-667. (Pubitemid 29465917)
192. Strassman AM, Raymond SA, Burstein R,. Sensitization of meningeal sensory neurons and the origin of headaches. Nature. 1996; 384: 560-564. (Pubitemid 26415932)
193. Burstein R, Yamamura H, Malisck A, Strassman AM,. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol. 1998; 79: 964-982. (Pubitemid 28095912)
194. Lipton RB, Bigal ME, Ashina S, et al,. Cutaneous allodynia in the migraine population. Ann Neurol. 2008; 63: 148-158. (Pubitemid 351355293)
195. Burstein R, Cutrer MF, Yarnitsky D,. The development of cutaneous allodynia during a migraine attack. Clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain. 2000; 123: 1703-1709. (Pubitemid 30481193)
196. Burstein R, Collins B, Jakubowski M,. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol. 2004; 55: 19-26. (Pubitemid 38067357)
197. Burstein R, Jkubowski M,. Analgesic action in an animal model of intracranial pain: A race against the development of central sensitization. Ann Neurol. 2004; 55: 27-36. (Pubitemid 38067358)
198. Levy D, Jakubowski M, Burstein R,. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A. 2004; 101: 4274-4279. (Pubitemid 38405919)
199. Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R,. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache. 2005; 45: 850-861. (Pubitemid 41045361)
200. Jakubowski M, Levy D, Kainz V, Zhang XC, Kosaras B, Burstein R,. Sensitization of central trigeminovascular neurons: Blockade by intravenous naproxen infusion. Neuroscience. 2007; 148: 573-583. (Pubitemid 47362497)
201. Linde M, Mellberg A, Dahlöf C,. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia. 2006; 26: 113-121.
202. Dahlöf C, Högenhuis L, Olesen J, et al,. Early clinical experience with subcutaneoes naratriptan in the acute treatment of migraine: A dose-ranging study. Eur J Neurol. 1998; 5: 469-477. (Pubitemid 28470001)
203. Tfelt-Hansen P,. Maximum effect of triptans in migraine? A comment. Cephalalgia. 2008; 26: 767-768. (Pubitemid 351799743)
204. Goadsby PJ, Zanchin G, Geraud G, et al,. Early vs. non-early intervention in acute migraine -"Act when mild (AwM)." A double-blind, placebo-controlled trial of almotriptan. Cephalalgia. 2008; 28: 383-391. (Pubitemid 351341454)
205. Goadsby PJ, Charbit AR, Andreou AP, Akerman S, Holland PR,. Neurobiology of migraine. Neuroscience. 2009; 161: 327-341.